Evidence map›Paper›PMID 40004228›Full record

ArticleInternational journal of molecular sciences2025

Application of an Integrated Single-Cell and Three-Dimensional Spheroid Culture Platform for Investigating Drug Resistance Heterogeneity and Epithelial-Mesenchymal Transition (EMT) in Lung Cancer Subclones.

Shin-Hu Chen, Jian-Hong Yu, Yu-Chun Lin, Yi-Ming Chang, Nien-Tzu Liu, Su-Feng Chen

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shin-Hu ChenDepartment of Dentistry, School of Dentistry, China Medical University, Taichung 40403, Taiwan.
Jian-Hong YuDepartment of Dentistry, School of Dentistry, China Medical University, Taichung 40403, Taiwan.
Yu-Chun LinDepartment of Pathology, National Defense Medical Center, Tri-Service General Hospital, Taipei 114201, Taiwan.
Yi-Ming ChangInstitute of Pathology and Parasitology, National Defense Medical Center, Taipei 11490, Taiwan.
Nien-Tzu LiuDepartment of Pathology, National Defense Medical Center, Tri-Service General Hospital, Taipei 114201, Taiwan.
Su-Feng ChenDepartment of Dentistry, School of Dentistry, China Medical University, Taichung 40403, Taiwan.ORCID 0000-0002-6044-5226

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is a leading cause of cancer-related mortality worldwide, largely due to its heterogeneity and intrinsic drug resistance. Malignant pleural effusions (MPEs) provide diverse tumor cell populations ideal for studying these complexities. Although chemotherapy and targeted therapies can be initially effective, subpopulations of cancer cells with phenotypic plasticity often survive treatment, eventually developing resistance. Here, we integrated single-cell isolation and three-dimensional (3D) spheroid culture to dissect subclonal heterogeneity and drug responses, aiming to inform precision medicine approaches. Using A549 lung cancer cells, we established a cisplatin-resistant line and isolated three resistant subclones (Holoclone, Meroclone, Paraclone) via single-cell sorting. In 3D spheroids, Docetaxel and Alimta displayed higher IC50 values than in 2D cultures, suggesting that 3D models better reflect clinical dosing. Additionally, MPE-derived Holoclone and Paraclone subclones exhibited distinct sensitivities to Giotrif and Capmatinib, revealing their heterogeneous drug responses. Molecular analyses confirmed elevated ABCB1, ABCG2, cancer stem cell (CSC) markers (OCT4, SOX2, CD44, CD133), and epithelial-mesenchymal transition (EMT) markers (E-cadherin downregulation, increased Vimentin, N-cadherin, Twist) in resistant subclones, correlating with enhanced migration and invasion. This integrated approach clarifies the interplay between heterogeneity, CSC/EMT phenotypes, and drug resistance, providing a valuable tool for predicting therapeutic responses and guiding personalized, combination-based lung cancer treatments.

Indexed as

Cell Culture Techniques, Three DimensionalDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionLung NeoplasmsSingle-Cell AnalysisSpheroids, CellularA549 CellsAntineoplastic AgentsCell Line, TumorCisplatinHumansNeoplastic Stem CellsAntineoplastic AgentsCisplatincancer stem cellsdrug resistanceepithelial–mesenchymal transitionlung cancersingle-cell culturetargeted therapythree-dimensional spheroid culture

Identifiers

PMID40004228
PMCPMC11855057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.